Jasper Therapeutics stock downgraded by William Blair on drug trial setbacks

Jasper Therapeutics (JSPR) was downgraded by William Blair to Market Perform following significant clinical trial complications, including an inactive drug product lot that delayed its pivotal Phase IIb CSU study to mid-2026 and led to the halt of its asthma program. The stock has plummeted 68% year-to-date. Despite these setbacks and a pipeline narrowing to focus on CSU, positive open-label extension data for briquilimab showed strong efficacy, prompting H.C. Wainwright to maintain a Buy rating while lowering its price target. JSPR anticipates needing to raise additional capital by Q4 2025, actively implementing cost-cutting measures.

Analysis

Jasper Therapeutics (JSPR) faces a significant operational and strategic crisis following a downgrade to Market Perform from William Blair, driven by severe complications in its clinical trials. The core issue is an inactive drug product lot, which has confounded results for its lead asset, briquilimab, in the BEACON study for chronic spontaneous urticaria (CSU). This manufacturing failure necessitates re-dosing and additional patient enrollment, pushing the initiation of the pivotal Phase IIb study to mid-2026 and delaying the data readout to Q4 2025. The fallout extends across the pipeline, forcing the company to halt its asthma program and discontinue development in genetic diseases, thereby concentrating significant risk onto the now-delayed CSU program. Despite the stock's -68% year-to-date decline, some positive signals remain; an open-label extension study showed a 73% complete response rate, and separate data in chronic inducible urticaria showed a 92% response rate, with no grade 3 or higher adverse events reported. This potential efficacy prompted H.C. Wainwright to maintain a Buy rating, though it halved its price target from $40 to $20, reflecting the extended timelines. The company is implementing cost-cutting measures but anticipates needing to raise additional capital by Q4 2025, introducing future dilution risk for shareholders.

Key Decisions for Investors

• Investors should recognize the heightened binary risk profile, as the company's valuation is now almost entirely dependent on the successful, albeit delayed, execution of the single briquilimab program for CSU.
• Factor in the significant and near-term shareholder dilution risk, given the company's stated need to raise additional capital by the fourth quarter of 2025 to fund operations through its extended clinical timeline.
• Monitor progress on resolving the manufacturing issues and watch for the delayed BEACON study data in Q4 2025 as the next key catalyst that could either validate the drug's potential or confirm the current negative sentiment.
• While the 68% stock decline may suggest a value opportunity, this is a high-risk situation where the low valuation directly reflects severe execution challenges and a protracted path to market.